Neo Ivy Capital Management Exact Sciences Corp Transaction History

Neo Ivy Capital Management

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Mar 24, 2023	BUY	$30.35 - $53.15 $182 - $318	6 New	6 $0
Q4 2021 Feb 15, 2022	SELL	$72.5 - $100.68 $89,102 - $123,735	-1,229 Closed	0 $0
Q3 2021 Nov 16, 2021	BUY	$90.24 - $124.05 $110,904 - $152,457	1,229 New	1,229 $107,000
Q2 2021 Aug 16, 2021	SELL	$93.66 - $139.27 $42,053 - $62,532	-449 Closed	0 $0
Q1 2021 Oct 07, 2021	BUY	$116.57 - $155.01 $52,339 - $69,599	449 New	449 $59,000
Q4 2020 Feb 16, 2021	SELL	$99.61 - $142.12 $122,121 - $174,239	-1,226 Closed	0 $0
Q3 2020 Nov 17, 2020	SELL	$72.92 - $102.01 $629,226 - $880,244	-8,629 Reduced 87.56%	1,226 $124,000
Q2 2020 Aug 17, 2020	BUY	$55.75 - $92.75 $480,899 - $800,061	8,626 Added 701.87%	9,855 $856,000
Q2 2020 Aug 17, 2020	BUY	$55.75 - $92.75 $68,516 - $113,989	1,229 New	1,229 $107,000
Q1 2020 May 15, 2020	SELL	$37.9 - $104.44 $151,713 - $418,073	-4,003 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$77.66 - $99.74 $310,872 - $399,259	4,003 New	4,003 $370,000
Q3 2019 Nov 21, 2019	SELL	$90.37 - $122.49 $890,596 - $1.21 Million	-9,855 Closed	0 $0
Q2 2019 Aug 15, 2019	BUY	$89.51 - $118.04 $882,121 - $1.16 Million	9,855 New	9,855 $1.16 Million

673

162M

2.58M

2.19M

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $10.2B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

Get notified when there are updates to the investment portfolio of Neo Ivy Capital Management, based on Form 13F filings with the SEC.

Stay updated on Neo Ivy Capital Management with notifications on news.